Psoriatic Arthritis | Pharmacor | G7 | 2014

Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-alpha (TNF-α) inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. Several novel therapies with alternative mechanisms of action are expected to launch for PsA during the 2013-2023 study period, and thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies.

The recent launches of the interleukin-12/-23 (IL-12/23) inhibitor ustekinumab (Janssen’s Stelara) and the oral phosphodiesterase-4 (PDE-4) inhibitor apremilast (Celgene’s Otezla) have heralded the post-TNF-α inhibitor era in the PsA market. In this report, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF-α inhibitor class.

Login to access report